Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX3902 in mCRPC and Advanced Solid Tumors
NCT07533708Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLX3902 in metastatic castration-resistant prostate cancer (mCRPC) and solid tumor, sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 2 years. Started Jul 2026; status: recruiting.
02
Drugs
HLX3902
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)solid tumor
Beyond the preview
Go deeper on NCT07533708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533708.